TRAVERSE BIOTECH II INC

Biotech · Private

HPX-612, an orally available small molecule NOD2 agonist immunotherapy for visceral leishmaniasis

Grants
$997K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · CD3 bispecific for the treatment of ROR2-positive NSCLC$399,955
Federal grantDepartment of Health and Human Services · Phase I · Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis$298,938
Federal grantDepartment of Health and Human Services · Phase I · Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis$297,717
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2731EPIGENTER, LLC——
2732OMETA LABS LLC——
2733IMAGEN BIOWORKS INC.——
2734TRAVERSE BIOTECH II INC——
2735INCOMPUTABLE LLC——
2736HYDROGENE THERAPEUTICS INC——
2737LUNA BIOSCIENCE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.